Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen A Harrison

Showing results (81-90 of 318) with videos related to

Pageof 32
Sort By:
Seminars in Liver Disease|October 29, 2008
Current and emerging therapies in nonalcoholic fatty liver diseaseMaryam R Kashi, Dawn M Torres, Stephen A Harrison
Hepatology (Baltimore, Md.)|March 19, 2013
Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association?Ryan M Kwok, Dawn M Torres, Stephen A Harrison
The Medical Clinics of North America|November 26, 2013
Review of treatment options for nonalcoholic fatty liver diseaseRichele L Corrado, Dawn M Torres, Stephen A Harrison
Journal of Hepatology|May 6, 2024
FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyondStephen A Harrison, Tim Rolph, Madeline Knott, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 27, 2012
Features, diagnosis, and treatment of nonalcoholic fatty liver diseaseDawn M Torres, Christopher D Williams, Stephen A Harrison
Clinical Liver Disease|June 13, 2019
Treatment of nonalcoholic fatty liver disease: Role of dietary modification and exerciseAngelo H Paredes, Dawn M Torres, Stephen A Harrison
Hepatology (Baltimore, Md.)|January 19, 2017
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical reviewVeeral H Ajmera, Norah A Terrault, Stephen A Harrison
Expert Review of Gastroenterology & Hepatology|August 30, 2012
Insulin resistance in chronic hepatitis C: the search for effective drug treatment continuesStephen A Harrison, Matthew J Lincoln, Katharine K Roberts
Hepatology (Baltimore, Md.)|December 5, 2023
Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver diseaseStephen A Harrison, Julie Dubourg, Maddie Knott, et al.
Journal of Hepatology|November 11, 2017
Pharmacotherapy for NASH: Current and emergingMonica A Konerman, Jacob C Jones, Stephen A Harrison
Pageof 32

Showing results (81-90 of 318) with videos related to

Sort By:
Pageof 32
Seminars in Liver Disease|October 29, 2008
Current and emerging therapies in nonalcoholic fatty liver diseaseMaryam R Kashi, Dawn M Torres, Stephen A Harrison
Hepatology (Baltimore, Md.)|March 19, 2013
Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association?Ryan M Kwok, Dawn M Torres, Stephen A Harrison
The Medical Clinics of North America|November 26, 2013
Review of treatment options for nonalcoholic fatty liver diseaseRichele L Corrado, Dawn M Torres, Stephen A Harrison
Journal of Hepatology|May 6, 2024
FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyondStephen A Harrison, Tim Rolph, Madeline Knott, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 27, 2012
Features, diagnosis, and treatment of nonalcoholic fatty liver diseaseDawn M Torres, Christopher D Williams, Stephen A Harrison
Clinical Liver Disease|June 13, 2019
Treatment of nonalcoholic fatty liver disease: Role of dietary modification and exerciseAngelo H Paredes, Dawn M Torres, Stephen A Harrison
Hepatology (Baltimore, Md.)|January 19, 2017
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical reviewVeeral H Ajmera, Norah A Terrault, Stephen A Harrison
Expert Review of Gastroenterology & Hepatology|August 30, 2012
Insulin resistance in chronic hepatitis C: the search for effective drug treatment continuesStephen A Harrison, Matthew J Lincoln, Katharine K Roberts
Hepatology (Baltimore, Md.)|December 5, 2023
Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver diseaseStephen A Harrison, Julie Dubourg, Maddie Knott, et al.
Journal of Hepatology|November 11, 2017
Pharmacotherapy for NASH: Current and emergingMonica A Konerman, Jacob C Jones, Stephen A Harrison
Pageof 32